Inventor · disambiguated record
Alexander Kiselyov
Also filed as: KISELYOV ALEXANDER · KISELYOV ALEXANDER S
14 granted patents·10 pending applications·100 citations·filing 2000–2021
90Inventor score
Files withSINGH JASBIR5DECODE GENETICS EHF4AMGEN INC3SONIC MASTER LTD3GENEA BIOCELLS USA HOLDINGS INC2
Top patents by PatentIndex Score
24 records- 0192US6995162B2Substituted alkylamine derivatives and methods of useAMGEN INC·Filed 2002·Granted Feb 7, 2006·48 cites·26 claims
- 0286US8642624B2Substituted alkylamine derivatives and methods of useCHEN GUOQING·Filed 2011·Granted Feb 4, 2014·11 cites·3 claims
- 0386US7875721B2Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereofSTC UNM·Filed 2006·Granted Jan 25, 2011·13 cites·23 claims
- 0482US6849639B2Integrin inhibitors and their methods of useAMGEN INC·Filed 2000·Granted Feb 1, 2005·19 cites·8 claims
- 0580US10258628B2Generation of muscle lineage cells and therapeutic uses thereofGENEA IP HOLDINGS PTY LTD·Filed 2018·Granted Apr 16, 2019·2 cites·24 claims
- 0679US8791267B2Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disordersSINGH JASBIR·Filed 2012·Granted Jul 29, 2014·4 cites·22 claims
- 0773US8883833B2Substituted benzoazole PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disordersSINGH JASBIR·Filed 2008·Granted Nov 11, 2014·1 cites·28 claims
- 0872US11065243B2Inhibitors of DUX4 induction for regulation of muscle functionSONIC MASTER LTD·Filed 2018·Granted Jul 20, 2021·1 cites·9 claims
- 0970US10933068B2Modulators of DUX4 for regulation of muscle functionGENEA BIOCELLS USA HOLDINGS INC·Filed 2017·Granted Mar 2, 2021·1 cites·15 claims
- 1065US2009136473A1Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disordersDECODE GENETICS EHF·Filed 2008·Application pending·0 cites
- 1164US2009324569A1Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disordersDECODE GENETICS EHF·Filed 2008·Application pending·0 cites
- 1261US2009318438A1Heterocyclic compounds and their use as anticancer agentsCHEN XIAOLING·Filed 2008·Application pending·0 cites
- 1361US2014301999A1Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disordersDECODE GENETICS EHF·Filed 2014·Application pending·0 cites
- 1458US2013273004A1Substituted alkylamine derivatives and methods of useAMGEN INC·Filed 2013·Application pending·0 cites
- 1557US11376257B2Generation of muscle lineage cells and therapeutic uses thereofGENEA BIOCELLS USA HOLDINGS INC·Filed 2019·Granted Jul 5, 2022·0 cites·3 claims
- 1657US7649113B2Mono, di and tri cyclic compounds useful for lowering IgE concentrationsUNIV NEW YORK STATE RES FOUND·Filed 2008·Granted Jan 19, 2010·0 cites·6 claims
- 1757US2012213758A1Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disordersSINGH JASBIR·Filed 2012·Application pending·0 cites
- 1857US2014275553A1Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disordersDECODE GENETICS EHF·Filed 2014·Application pending·0 cites
- 1956US11806343B2Inhibitors of DUX4 induction for regulation of muscle functionSONIC MASTER LTD·Filed 2021·Granted Nov 7, 2023·0 cites·5 claims
- 2052US2021196723A1Modulators of DUX4 for Regulation of Muscle FunctionSONIC MASTER LTD·Filed 2021·Application pending·0 cites
- 2152US2012207729A1Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disordersSINGH JASBIR·Filed 2012·Application pending·0 cites
- 2249US2009048301A1Heterocyclic compounds and their use as anticancer agentsIMCLONE SYSTEMS INC·Filed 2004·Application pending·0 cites
- 2348US8877816B24-(or 5-) substituted catechol derivativesSINGH JASBIR·Filed 2008·Granted Nov 4, 2014·0 cites·29 claims
- 2445US7425655B2Mono di & tri cyclic compounds useful for lowering IgE concentrationsUNIV NEW YORK STATE RES FOUND·Filed 2004·Granted Sep 16, 2008·0 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Alexander Kiselyov files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →